Alisha Kang

668 total citations
8 papers, 218 citations indexed

About

Alisha Kang is a scholar working on Immunology, Infectious Diseases and Health. According to data from OpenAlex, Alisha Kang has authored 8 papers receiving a total of 218 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 5 papers in Infectious Diseases and 4 papers in Health. Recurrent topics in Alisha Kang's work include Immune responses and vaccinations (7 papers), SARS-CoV-2 and COVID-19 Research (4 papers) and Vaccine Coverage and Hesitancy (4 papers). Alisha Kang is often cited by papers focused on Immune responses and vaccinations (7 papers), SARS-CoV-2 and COVID-19 Research (4 papers) and Vaccine Coverage and Hesitancy (4 papers). Alisha Kang collaborates with scholars based in Canada and China. Alisha Kang's co-authors include Sam Afkhami, Zhou Xing, Mangalakumari Jeyanathan, Amy Gillgrass, Ramandeep Singh, Xiang‐Qian Luo, Maryam Vaseghi‐Shanjani, Anna Zganiacz, Ramandeep Singh and Anna Dvorkin‐Gheva and has published in prestigious journals such as Nature Immunology, The FASEB Journal and Cell Reports.

In The Last Decade

Alisha Kang

7 papers receiving 215 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alisha Kang Canada 7 117 110 43 33 31 8 218
Μαρία Τσιλικά Greece 3 239 2.0× 112 1.0× 51 1.2× 59 1.8× 84 2.7× 7 291
Jaewon Kang United States 7 75 0.6× 179 1.6× 27 0.6× 21 0.6× 20 0.6× 11 232
Ane Fernandez Salinas Italy 7 131 1.1× 139 1.3× 22 0.5× 14 0.4× 14 0.5× 8 238
Dearbhla M Murphy Ireland 6 161 1.4× 102 0.9× 53 1.2× 12 0.4× 24 0.8× 14 285
Ida Jarlhelt Denmark 11 50 0.4× 218 2.0× 88 2.0× 22 0.7× 19 0.6× 15 319
John S. Burke United States 6 76 0.6× 258 2.3× 37 0.9× 20 0.6× 12 0.4× 9 301
Clara David Belgium 7 42 0.4× 213 1.9× 28 0.7× 7 0.2× 37 1.2× 12 245
Julia Barrett United States 5 84 0.7× 281 2.6× 68 1.6× 13 0.4× 32 1.0× 8 319
Tatiana Roy Belgium 6 34 0.3× 220 2.0× 36 0.8× 7 0.2× 52 1.7× 8 270
Maren Bacher Germany 3 67 0.6× 358 3.3× 90 2.1× 13 0.4× 53 1.7× 4 380

Countries citing papers authored by Alisha Kang

Since Specialization
Citations

This map shows the geographic impact of Alisha Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alisha Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alisha Kang more than expected).

Fields of papers citing papers by Alisha Kang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alisha Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alisha Kang. The network helps show where Alisha Kang may publish in the future.

Co-authorship network of co-authors of Alisha Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Alisha Kang. A scholar is included among the top collaborators of Alisha Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alisha Kang. Alisha Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Kang, Alisha, Michael R. D’Agostino, Sam Afkhami, Mangalakumari Jeyanathan, & Zhou Xing. (2025). Resident memory macrophages and trained innate immunity at barrier tissues. eLife. 14.
2.
Kang, Alisha, Sam Afkhami, Kanwaldeep Singh, et al.. (2024). LPS-induced lung tissue-resident trained innate immunity provides differential protection against pneumococci and SARS-CoV-2. Cell Reports. 43(10). 114849–114849. 9 indexed citations
3.
Afkhami, Sam, et al.. (2023). Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19. Current Opinion in Virology. 61. 101334–101334. 8 indexed citations
4.
Kang, Alisha, Ramandeep Singh, Sam Afkhami, et al.. (2023). Subcutaneous BCG vaccination protects against streptococcal pneumonia via regulating innate immune responses in the lung. EMBO Molecular Medicine. 15(7). e17084–e17084. 17 indexed citations
5.
Jeyanathan, Mangalakumari, Sam Afkhami, Alisha Kang, & Zhou Xing. (2023). Viral-vectored respiratory mucosal vaccine strategies. Current Opinion in Immunology. 84. 102370–102370. 9 indexed citations
6.
Jeyanathan, Mangalakumari, Maryam Vaseghi‐Shanjani, Sam Afkhami, et al.. (2022). Parenteral BCG vaccine induces lung-resident memory macrophages and trained immunity via the gut–lung axis. Nature Immunology. 23(12). 1687–1702. 101 indexed citations
7.
D’Agostino, Michael R., Sam Afkhami, Alisha Kang, et al.. (2022). Protocol for isolation and characterization of lung tissue resident memory T cells and airway trained innate immunity after intranasal vaccination in mice. STAR Protocols. 3(3). 101652–101652. 6 indexed citations
8.
Singh, Ramandeep, Alisha Kang, Xiang‐Qian Luo, et al.. (2021). COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development. The FASEB Journal. 35(3). e21409–e21409. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026